Search Filters

  • Media Source
  • Presentation Format
  • Media Type
  • Media Year
  • Language
  • Diagnosis / Condition
  • Diagnosis Method
  • Patient Populations
  • Treatment / Technique

Costal Chondrocyte-Derived Pellet-Type Autologous Chondrocyte Implantation vs. Microfracture for Repair of Articular Cartilage Defects

Costal Chondrocyte-Derived Pellet-Type Autologous Chondrocyte Implantation vs. Microfracture for Repair of Articular Cartilage Defects

Dae Keun Suh, MD, PhD, KOREA, REPUBLIC OF Kyoung Ho Yoon, MD, PhD, Prof., KOREA, REPUBLIC OF Cheol Hee Park, MD, PhD, KOREA, REPUBLIC OF Sang-Gyun Kim, MD, PhD, KOREA, REPUBLIC OF Jae-Young Park, MD, KOREA, REPUBLIC OF Yoon-Seok Kim, MD, KOREA, REPUBLIC OF Hee Sung Lee, MD, KOREA, REPUBLIC OF Sung Hyun Hwang, MD, KOREA, REPUBLIC OF Bo Seung Bae, MD, KOREA, REPUBLIC OF

Kyung Hee University Hospital, Seoul, KOREA, REPUBLIC OF


2023 Congress   ePoster Presentation   2023 Congress   Not yet rated

 

Anatomic Location

Anatomic Structure

Diagnosis / Condition

Patient Populations

Diagnosis Method

MRI


Summary: Costal chondrocyte-derived pellet-type autologous chondrocyte implantation for repair of articular cartilage defects


Background

Costal chondrocyte-derived pellet-type autologous chondrocyte implantation(CCP-ACI) has been introduced as a new therapeutic option for treatment of articular cartilage defect. We had previously conducted a randomized controlled trial comparing CCP-ACI versus microfracture at 1 year. Patients were followed up at 5 years for clinical and radiological evaluation.

Purpose

To study the efficacy and safety results at 5 years of CCP-ACI versus microfracture.

Methods

This article describes the 5-year follow-up of a previous prospective clinical trial that compared the results of CCP-ACI versus microfracture at 1-year follow-up. Of the 30 patients from the CCP-ACI group that were described in the previous study, 25 were followed-up. Clinical outcomes score and magnetic resonance imaging was performed at last follow-up.

Results

MOCART scores improved significantly from baseline to 5 years postoperatively only in the CCP-ACI group (P < 0.0001). The MOCART scores in the CCP-ACI group was significantly greater than that in the MFx group at 5 years (70.9 vs 26.7, P < 0.0001). The Lysholm score and KOOS score in the CCP-ACI group was significantly greater than that in the MFx group at 5 years (84.5 vs 64.9 and 390.9 vs 303.0, P = 0.023 and P = 0.038, respectively).

Conclusion

Treatment of cartilage defects with CCP-ACI yielded better clinical and radiologic outcome compared to microfracture at 5 years.


More 2023 ISAKOS Congress Content